Conditions: Allergies
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 220
Healthy volunteers: yes

Brief summary:
The primary objective of this study was to determine whether children ages 6-11 years prefer desloratadine RediTabs (2.5 mg) or a marketed competitor (Zyrtec® 5 mg Chewable Tablets). The secondary objectives of this study were to compare acceptance of the two attributes, taste and feeling in the mouth, of desloratadine 2.5 mg RediTabs and Zyrtec® 5 mg Chewable Tablets

Detailed description:

Arms:
arm 1: Subjects received a single dose of desloratadine RediTab followed 8-10 minutes later by a single dose of Zyrtec chewable tablet followed thereafter by a statement of preference. arm 2: Subjects received a single dose of Zyrtec chewable tablet followed 8-10 minutes later by a single dose of desloratadine RediTab followed thereafter by a statement of preference.

Interventions: intervention 1: Desloratadine intervention 2: Zyrtec® (cetirizine)
Intervention descriptions: intervention 1: desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day intervention 2: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day

Protocol document: